Sign In
Buy SRPT
$16.24
-0.0100 (-0.0615%)
At Close: Jun 03, 2026
NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023
The Gross Law Firm Notifies Shareholders of Sarepta Therapeutics, Inc.(SRPT) of a Class Action Lawsuit and an Upcoming Deadline
04:23pm, Wednesday, 30'th Jul 2025
NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT).
Sarepta Therapeutics (SRPT) Tanks 36% After 3rd Patient Death, SRPT Securities Class Action Pending – Hagens Berman
03:16pm, Wednesday, 30'th Jul 2025
SAN FRANCISCO, July 30, 2025 (GLOBE NEWSWIRE) -- On July 18, 2025, investors saw the price of their shares in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) collapse again – this time, shares closed down
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
11:07am, Wednesday, 30'th Jul 2025
In May, FDA Commissioner Marty Makary named Vinay Prasad the next director of the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER). Within three months, Pr
Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth
11:06am, Wednesday, 30'th Jul 2025
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law before the August 25, 2025 securities fraud class action deadline.
Opinion | On Sarepta, a Welcome FDA Reversal
05:48pm, Tuesday, 29'th Jul 2025
After our editorial, the agency relents to allow a Duchenne treatment.
Sarepta finally gets some good news: A patient death wasn't its DMD drug's fault.
02:47pm, Tuesday, 29'th Jul 2025
Sarepta Therapeutics' stock was soaring Tuesday after the FDA recommended lifting the pause on the company's Duchenne muscular dystrophy drug, but analysts worry it will take time for patients and doc
SRPT Rallies on FDA Green Light: A New Bottom for the Stock?
02:06pm, Tuesday, 29'th Jul 2025
Sarepta Therapeutics (SRPT) jumped on Tuesday's session after the FDA lifted a voluntary pause on the company's gene therapy treatment for patients with Duchenne muscular dystrophy. The drug was pulle
FDA Lifts Safety Hold On Sarepta's Muscular Dystrophy Gene Therapy—Wall Street Cheers
01:27pm, Tuesday, 29'th Jul 2025
As gene therapies continue to evolve as a promising frontier in medical treatment, regulatory scrutiny intensifies following safety concerns. Recent developments with Sarepta Therapeutics Inc SRPT hig
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
10:40am, Tuesday, 29'th Jul 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options If you su
Sarepta shares surge after FDA lifts pause on muscular dystrophy treatment
10:24am, Tuesday, 29'th Jul 2025
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares jumped 25% at the open on Tuesday after the US Food and Drug Administration recommended the company lift a voluntary pause on shipments of its gene therap
Sarepta: SRPT Stock To $40?
09:00am, Tuesday, 29'th Jul 2025
Sarepta Therapeutics is trading around $19 in extended hours following the FDA's decision to remove the pause on Elevidys, marking a critical turning point for the beleaguered biotech. This regulatory
NEW YORK , July 29, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS
Sarepta shares soar 36% after FDA clears partial resumption of Elevidys shipments
08:38am, Tuesday, 29'th Jul 2025
Sarepta Therapeutics shares jumped over 36% in premarket trading on Tuesday after the company said it had received US Food and Drug Administration (FDA) approval to restart shipments of its flagship g
